IGM Biosciences to Present at the 40th Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/05/22
IGM Biosciences Presents Clinical Data from IGM-2323 in Patients with Advanced B Cell Malignancies at 2021 American Society of Hematology Annual MeetingGlobeNewsWire • 12/11/21
IGM Biosciences to Collaborate on the Study of IgM and IgA Antibodies for the Prevention of MalariaGlobeNewsWire • 12/08/21
IGM Biosciences to Host Conference Call and Webcast to Review IGM-2323 Data Presented at the 63rd Annual ASH MeetingGlobeNewsWire • 12/06/21
IGM Biosciences Announces Third Quarter 2021 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/04/21
IGM Biosciences Announces Leadership Appointments and Formation of IGM Infectious Diseases and IGM Autoimmunity and Inflammation Business UnitsGlobeNewsWire • 10/11/21
IGM Biosciences to Present at the 2021 Cantor Virtual Global Healthcare ConferenceGlobeNewsWire • 09/23/21
IGM Biosciences Announces Second Quarter 2021 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/09/21
5 Mid-Cap Healthcare Stocks You'll Want on Your Radar for the 2nd Half of 2021The Motley Fool • 07/23/21
IGM Biosciences Announces Expansion of IgM Platform into Infectious Diseases, Publication of Preclinical Data in Nature Demonstrating Engineered IgM Antibody Antiviral Activity for the Treatment and Prevention of COVID-19GlobeNewsWire • 06/03/21
IGM Biosciences Announces First Quarter 2021 Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/06/21
IGM Biosciences, Inc. (IGMS) CEO Fred Schwarzer on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 03/31/21
IGM Biosciences Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate UpdateGlobeNewsWire • 03/30/21
Last patient with liver cancer included in the monotherapy part of Medivir's phase Ib study with MIV-818PRNewsWire • 03/25/21